{"contraindications":{"vaccineGroup":{"contraindication":[{"observationCode":"095","observationTitle":"Severe allergic reaction after previous dose of Meningococcal","contraindicationText":"Do not vaccinate if the patient has had a severe allergic reaction after a previous dose of Meningococcal vaccine."},{"observationCode":"080","observationTitle":"Adverse reaction to vaccine component","contraindicationText":"Do not vaccinate if the patient has had an adverse reaction to a vaccine component."}]},"vaccine":{"contraindication":[{"observationCode":"154","observationTitle":"HIV/AIDS - severely immunocompromised","contraindicationText":"Do not vaccinate with Meningococcal MCV4P (Menactra) if the patient is between the ages of 9 months and 2 years and is severely immunocompromised due to HIV/AIDS.","contraindicationGuidance":"n/a","contraindicatedVaccine":[{"vaccineType":"Meningococcal, MCV4P","cvx":"114","beginAge":"2 months","endAge":"2 years"}]},{"observationCode":"155","observationTitle":"HIV/AIDS - not severely immunocompromised","contraindicationText":"Do not vaccinate with Meningococcal MCV4P (Menactra) if the patient is between the ages of 9 months and 2 years and is severely immunocompromised due to HIV/AIDS.","contraindicationGuidance":"n/a","contraindicatedVaccine":[{"vaccineType":"Meningococcal, MCV4P","cvx":"114","beginAge":"2 months","endAge":"2 years"}]},{"observationCode":"160","observationTitle":"Anatomical or functional asplenia","contraindicationText":"Do not vaccinate with Meningococcal MCV4P (Menactra) if the patient is between the ages of 9 months and 2 years and has anatomical or functional asplenia.","contraindicationGuidance":"n/a","contraindicatedVaccine":[{"vaccineType":"Meningococcal, MCV4P","cvx":"114","beginAge":"2 months","endAge":"2 years"}]},{"observationCode":"117","observationTitle":"Severe allergic reaction to diphtheria toxoid","contraindicationText":"Do not vaccinate if the patient has had a severe allergic reaction to diphtheria toxoid.","contraindicationGuidance":"n/a","contraindicatedVaccine":[{"vaccineType":"Meningococcal, MCV4P","cvx":"114"},{"vaccineType":"Meningococcal, MCV4O","cvx":"136"}]},{"observationCode":"118","observationTitle":"Severe allergic reaction to tetanus toxoid","contraindicationText":"Do not vaccinate if the patient has had a severe allergic reaction to tetanus toxoid.","contraindicationGuidance":"n/a","contraindicatedVaccine":[{"vaccineType":"Meningococcal Polysaccharide A, C, Y, W-135 TT Conjugate"}]}]}},"series":[{"seriesName":"Meningococcal ACWY 2-dose series","targetDisease":"Meningococcal","vaccineGroup":"Meningococcal","seriesType":"Standard","equivalentSeriesGroups":"2","selectSeries":{"defaultSeries":"Yes","productPath":"No","seriesGroupName":"Standard","seriesGroup":"1","seriesPriority":"A","seriesPreference":"1"}},{"seriesName":"Meningococcal ACWY risk start before 7 months 4-dose series","targetDisease":"Meningococcal","vaccineGroup":"Meningococcal","seriesAdminGuidance":["If MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses."],"seriesType":"Risk","selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Increased Risk","seriesGroup":"2","seriesPriority":"A","minAgeToStart":"2 months","maxAgeToStart":"7 months"},"indication":[{"observationCode":{"text":"Persons at risk during an outbreak","code":"070"},"description":"Administer to persons identified as at increased risk during a community outbreak attributable to a vaccine serogroup","beginAge":"2 months"},{"observationCode":{"text":"Persistent complement, properdin, or factor B deficiency","code":"151"},"description":"Administer to persons who have persistent complement deficiencies","beginAge":"2 months"},{"observationCode":{"text":"Anatomical or functional asplenia","code":"160"},"description":"Administer to persons with anatomic or functional asplenia, including sickle cell disease.","beginAge":"2 months"},{"observationCode":{"text":"Travel to or are residents of countries in which meningococcal disease is hyperendemic or epidemic","code":"164"},"description":"Administer to persons who travel to or are residents of countries in which meningococcal disease is hyperendemic or epidemic","beginAge":"2 months"},{"observationCode":{"text":"HIV Infection"},"description":"Administer to persons with HIV Infection","beginAge":"2 months"}]},{"seriesName":"Meningococcal ACWY risk start after 7 months 2-dose series","targetDisease":"Meningococcal","vaccineGroup":"Meningococcal","seriesAdminGuidance":["If MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses."],"seriesType":"Risk","selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Increased Risk","seriesGroup":"2","seriesPriority":"A","minAgeToStart":"7 months","maxAgeToStart":"2 years"},"indication":[{"observationCode":{"text":"Persons at risk during an outbreak","code":"070"},"description":"Administer to persons identified as at increased risk during a community outbreak attributable to a vaccine serogroup","beginAge":"7 months"},{"observationCode":{"text":"Persistent complement, properdin, or factor B deficiency","code":"151"},"description":"Administer to persons who have persistent complement deficiencies","beginAge":"7 months"},{"observationCode":{"text":"Anatomical or functional asplenia","code":"160"},"description":"Administer to persons with anatomic or functional asplenia, including sickle cell disease.","beginAge":"7 months"},{"observationCode":{"text":"Travel to or are residents of countries in which meningococcal disease is hyperendemic or epidemic","code":"164"},"description":"Administer to persons who travel to or are residents of countries in which meningococcal disease is hyperendemic or epidemic","beginAge":"7 months","guidance":"If an infant is receiving the vaccine prior to travel, 2 doses may be administered as early as 8 weeks apart."},{"observationCode":{"text":"HIV Infection"},"description":"Administer to persons with HIV Infection","beginAge":"7 months"}]},{"seriesName":"Meningococcal ACWY risk Hib-MenCY-TT 4-dose series","targetDisease":"Meningococcal","vaccineGroup":"Meningococcal","seriesType":"Risk","selectSeries":{"defaultSeries":"No","productPath":"Yes","seriesGroupName":"Increased Risk","seriesGroup":"2","seriesPriority":"A","minAgeToStart":"2 months","maxAgeToStart":"16 months"},"indication":[{"observationCode":{"text":"Persons at risk during an outbreak","code":"070"},"description":"Administer to persons identified as at increased risk during a community outbreak attributable to a vaccine serogroup","beginAge":"2 months"},{"observationCode":{"text":"Persistent complement, properdin, or factor B deficiency","code":"151"},"description":"Administer to persons who have persistent complement deficiencies","beginAge":"2 months"},{"observationCode":{"text":"Anatomical or functional asplenia","code":"160"},"description":"Administer to persons with anatomic or functional asplenia, including sickle cell disease.","beginAge":"2 months"}]},{"seriesName":"Meningococcal ACWY risk 2-dose series","targetDisease":"Meningococcal","vaccineGroup":"Meningococcal","seriesAdminGuidance":["If MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses."],"seriesType":"Risk","selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Increased Risk","seriesGroup":"2","seriesPriority":"A","minAgeToStart":"2 months"},"indication":[{"observationCode":{"text":"Persistent complement, properdin, or factor B deficiency","code":"151"},"description":"Administer to persons who have persistent complement deficiencies","beginAge":"2 years"},{"observationCode":{"text":"Anatomical or functional asplenia","code":"160"},"description":"Administer to persons with anatomic or functional asplenia, including sickle cell disease.","beginAge":"2 years"},{"observationCode":{"text":"HIV Infection"},"description":"Administer to persons with HIV Infection","beginAge":"2 months"}]},{"seriesName":"Meningococcal ACWY risk 1-dose series","targetDisease":"Meningococcal","vaccineGroup":"Meningococcal","seriesAdminGuidance":["If MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses. ","Persons with HIV infection who are recommended routinely to receive vaccine should receive a 2-dose primary series, administered 8-12 weeks apart, because evidence suggests that persons with HIV do not respond optimally to a single dose."],"seriesType":"Risk","selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Increased Risk","seriesGroup":"2","seriesPriority":"B","minAgeToStart":"2 years"},"indication":[{"observationCode":{"text":"College students living in residence halls","code":"046"},"description":"Administer to college students living in residence halls.","beginAge":"19 years","endAge":"22 years"},{"observationCode":{"text":"Microbiologists routinely exposed to Neisseria meningitidis","code":"050"},"description":"Administer to microbiologists routinely exposed to Neisseria meningitidis","beginAge":"19 years"},{"observationCode":{"text":"Military recruits","code":"064"},"description":"Administer to military recruits.","beginAge":"19 years"},{"observationCode":{"text":"Persons at risk during an outbreak","code":"070"},"description":"Administer to persons identified as at increased risk during a community outbreak attributable to a vaccine serogroup.","beginAge":"2 years"},{"observationCode":{"text":"Travel to or are residents of countries in which meningococcal disease is hyperendemic or epidemic","code":"164"},"description":"Administer to persons who travel to or are residents of countries in which meningococcal disease is hyperendemic or epidemic.","beginAge":"2 years"}]}]}